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Stlmmary 
During thymic maturation, CD4-CD8-TCR-  immature thymocytes differentiate through a 
CD4+CD8+TCR  1~ intermediate into two functionally distinct  mature T  cell subsets: helper 
T cells expressing CD4 and a major histocompatibility  complex (MHC) class II-restricted T 
cell receptor (TCR), and cytotoxic T cells expressing CD8 and an MHC class I-restricted TCR. 
The mutually exclusive  expression of CD4 and CD8 is maintained in the periphery during expansion 
of these mature T cell subsets. To elucidate the mechanisms controlling CD4 and CD8 expression 
on differentiating  thymocytes and mature peripheral T ceils, we have examined the expression 
of human CD4 gene constructs in the lymphoid tissues of transgenic mice. Our analyses  demonstrate 
that sequences contained  within or closely linked  to the human CD4 gene are sufficient to 
reconstitute the appropriate regulation of human CD4 expression on all thymocyte and mature 
peripheral T cell subsets. Specifically, appropriate developmental regulation was dependent on 
two sets of sequences, one contained within a 1.3-kb restriction fragment located 6.5 kb upstream 
of the human CD4 gene, and the other present within or immediately flanking the gene. Nucleotide 
sequence analysis identified the 1.3-kb restriction fragment as the likely human homologue of 
an enhancer found 13 kb upstream of the mouse CD4 transcription  initiation site. The human 
CD4 transgenic mice provide a useful system for the identification and characterization of additional 
sequence elements that participate  in human CD4 gene regulation and for the elucidation  of 
regulatory mechanisms governing the developmental program mediating the maturation of the 
CD4 + and CD8 + peripheral  T  cell subsets. 
M 
ature  CD4+CD8 -  class II-restricted  and  CD4- 
CD8 +  class I-restricted  lymphocytes differentiate 
intrathymically from CD4-CD8- TCR- cells that originate 
from fetal liver or bone marrow precursors (1). The major 
intermediate in the T cell differentiation  pathway is the double- 
positive thymocyte, which expresses  both CD4 and CD8 and 
low levels of the od3 TCR. Antibody blocking experiments 
(2, 3), as well as more recent studies in gene knockout mice 
(4, 5), have demonstrated that CD4 and CD8 are essential 
for the differentiation of double-positive thymocytes into ma- 
ture class II- and class I-restricted T cells, respectively. On 
mature T cells, CD4 and CD8 participate in Ag recognition 
and T cell activation by binding to monomorphic  determinants 
on MHC class II and class I proteins, respectively (6-12). Co- 
engagement of an Ag-MHC complex by an c~/3 TCR and 
either CD4 or CD8 is believed to be a critical component 
of the T cell activation pathway (13-17). The lymphocyte- 
specific tyrosine kinase, p56  lck, is physically associated with 
the cytoplasmic domains of both CD4 and CD8 and can be 
activated by antibody crosslinking of either of these glyco- 
proteins (18-21). Thus, coengagement of Ag-MHC by the 
TCR and CD4 or CD8 may trigger T cell activation by trans- 
ducing transmembrane signals via p56  lck (22, 23). By bind- 
ing MHC, CD4 and CD8 may also contribute to T cell acti- 
vation as adhesion molecules that increase the avidity of T 
cell/target cell interactions  (24-26).  On maturing thymo- 
cytes, as on peripheral T calls, the functions of CD4 and CD8 
are mediated through their binding to MHC proteins, either 
as coreceptors and/or as adhesion molecules (27-29). 
The pattern of CD4 and CD8 expression during thymo- 
cyte development is quite complex.  In the mouse, CD4 is 
expressed at low levels on multipotential hemopoietic stem 
cells in bone marrow (30) and on the earliest detectable thymic 
precursor  calls (31), which subsequently  differentiate into 
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surface expression is later regained at the double-positive stage, 
when CD4 is coexpressed with CD8.  Included within this 
double-positive subset are thymocytes that have productively 
rearranged  and assembled ol/fl TCRs on the cell surface. Upon 
positive selection, CD4 +  CD8 + cells differentiate into CD4 + 
CD8-  and CD4-CD8 + single-positive thymocytes that ex- 
press,  respectively,  class  II-  and  class  I-restricted  TCRs 
(reviewed in reference 32). Thus, the maturation of a CD4 + 
CD8 + double-positive thymocyte into  a class II-restricted 
T cell involves the loss of CD8 cell surface expression,  whereas 
the maturation of a class I-restricted T cell involves the loss 
of CD4 cell surface expression.  The loss of CD4 or CD8 
expression  during  T  cell  selection is  accompanied by the 
differentiation  of double-positive cells into mature thymo- 
cytes, which exhibit increased surface levels of TCR and cease 
TCR oe chain gene rearrangement  (33, 34).  The mutually 
exclusive loss of CD4 or CD8 coreceptor expression is also 
associated with the commitment of thymic precursors to ei- 
ther the mature cytotoxic or helper T  cell phenotype. Pre- 
sumably, the developmental decision to mature and to commit 
to a functional  T  cell phenotype involves changes in gene 
expression.  Therefore, the study of CD4 and CD8 gene regu- 
lation during  thymocyte development  should enhance our 
general understanding of the mechanisms governing the ap- 
parent reprogramming of gene activity during the differenti- 
ation of the mature T  cell subclasses. 
The strict correlation between TCR specificity and CD4/ 
CD8 coreceptor expression indicates that the regulation of 
CD4 and CD8 expression must be inextricably tied to the 
T  cell selection process. Although it is known from studies 
on TCR. transgenic mice that the specificity of an c~//~/TCR. 
for MHC class I or class II molecules determines the CD4- 
CD8 +/CD4+CD8 -  phenotype of a mature T cell (35-38), 
the mechanism by which TCR specificity dictates the CD4 
or CD8 phenotype has yet to be elucidated. Two models have 
been formulated to describe the regulation of CD4 and CD8 
expression during  the  selection of mature  thymocytes: in- 
struction and stochastic/selection (39-41). In the most widely 
discussed form of the instruction model the CD4 and CD8 
genes are continuously transcribed in the CD4 § CD8 + cell, 
and coengagement of MHC by the TCR and CD4 or CD8 
sends a signal to turn off either CD8 or CD4 gene transcrip- 
tion, respectively. In the stochastic/selection model, on the 
other hand, the CD4 or CD8 genes are transcriptionally si- 
lenced by a mechanism that acts independently of the MHC 
class specificity of the TCR, and the process of positive selec- 
tion chooses those cells with  the appropriate combination 
of CD4/CD8  and  class  I/II-restricted  TCR.  for  further 
differentiation.  Studies on CD8 transgenic mice are consis- 
tent with the predictions of the instruction model (42-44). 
However, on the basis of analyses of neonatal thymocytes in 
class  I-restricted  TCR transgenic  mice (45)  and of T  cell 
subsets in dass II knockout mice (46, 47), other investigators 
have argued for the existence of a stochastic component to 
the appearance of the single-positive subsets. Northern anal- 
yses of CD4+CD8 -  and CD4-CD8 + PBL indicate that the 
expression of the CD4 and CD8 genes is transcriptionally 
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controlled in mature T cells (48, 49), and both the instruc- 
tion and stochastic/selection  models make the assumption that 
the loss of CD4 or CD8 expression during thymocyte matu- 
ration is also mediated at the transcriptional level. However, 
little data exist on the transcriptional  states of the CD4 and 
CD8  genes during  T  cell development in the thymus. 
As a first step toward elucidating the mechanisms control- 
ling CD4 and CD8 expression during the selection of ma- 
ture thymocytes, we have examined the expression of three 
different human CD4 gene constructs in the lymphoid tissues 
of transgenic mice. One construct expresses the human CD4 
transgene preferentially on mouse CD4 + T  cells, including 
the CD4+CD8 + and CD4+CD8 -  thymic and the CD4 + 
CD8-  splenic T cell subsets.  Comparison of the three trans- 
genes shows that the developmentally appropriate expression 
of a human CD4 transgene is dependent on a T cell-specific 
enhancer located 6.5 kb upstream of the CD4 gene and on 
sequences within or immediately flanking the gene.  These 
findings demonstrate that the developmental reprogramming 
of human CD4 expression during thymocyte selection is medi- 
ated by sequences closely linked to the CD4 gene. Thus, the 
human CD4 transgenic mouse system described in these studies 
can be used to further dissect the regulatory mechanisms gov- 
erning CD4 gene expression during thymocyte maturation. 
Materials and Methods 
Human CD4 Transgene Constructs.  Two human CD4 genomic 
clones, Magl and )~hg6, were kindly provided by D. R. Littman 
(University of California, San Francisco) for the construction  of 
CD4-1.  The insert  of )xhgl begins at a HindllI site 3.5 kb up- 
stream of the transcriptional  initiation  site and ends within the 
first 1 kb of the third intron,  and the insert in )xhg6 begins within 
the third intron, '~2 kb upstream of exon 4, and ends 9.5 kb down- 
stream of exon 10. The inserts from these )~ clones were recloned 
into pBluescript I (Stratagene, La Jolh, CA) to generate the plasmids 
phgLKS5 and phg6SK9. The phgLKS5 phsmid was partially digested 
with EcoRI, which cuts at either end of the insert. Linear 20-kb 
molecules (17-kb insert plus 3-kb vector) were then separated from 
form II DNA, and the 17-kb insert was separated by pulsed field 
gel electrophoresis (PFGE). The linear fragment  was isolated by 
electroelution and then dephosphorylated by calf intestinal phos- 
phatase (CIP). The EcoRI insert of phg6SK9 (18 kb) was purified 
from the pBluescript vector by gel dectrophoresis  and electroelu- 
tion and then ligated to linearized phglKS5 at 10/~g/ml. All trans- 
formants were screened by colony hybridization  (50) to identify 
those colonies containing hg6 inserts. Miniprep DNA was prepared 
from those colonies hybridizing to an hg6-specific probe and ana- 
lyzed by digestion with HindlII and BamHI to identify clones in 
the correct orientation.  This yielded CD4-1  (51). 
The 1.3-kb SphI-ClaI restriction  fragment was obtained from 
a cosmid clone isolated from a pWE15 human placental DNA cosmid 
library kindly provided by G. A. Evans (Salk Institute). Three over- 
lapping human CD4 cosmid clones were identified after a screen 
of 4.5  x  105 clones with a radiolabeled 0.5-kb EcoRI-SacI frag- 
ment of the human CD4 promoter (51). The 1.3-kb SphI-ClaI frag- 
ment was isolated from one of these clones, gel purified, ligated 
to Sail linkers (New England Biolabs, Inc., Beverly,  MA), and then 
subdoned into the SalI site of pBluescript II (Stratagene), creating 
pBluescript  1.3 SalI. 
Human CD4 Transgene The 1.3 CD4-1 transgene construct was generated by ligation 
of the  gel-purified  1.3-kb SalI-SalI restriction  fragment  from 
pBluescript 1.3 SalI to the SalI-linearized  pBluescript CD4-1 con- 
struct. 
The 1.3 mouse CD3-human CD4 cDNA/gcnomic (1.3 mCD3- 
hCD4c/g) transgene construct was prepared by ligating the 1.3-kb 
SphI-ClaI restriction fragment to a human CD4 minigene. This 
minigene was obtained from pNEZT4 (described in D. Grass, A. 
Garvin, I3. Littman, N. Lee, and E. Lacy,  manuscript in prepara- 
tion) and consists of  an EcoRI-SacI  cDNA fragment encoding  exons 
2-4 and part of exon 5 fused to a genomic SacI-BamHI fragment 
encoding the remainder of exons 5, 6-9, and part of 10 (49). The 
transcriptional initiation and termination signals of the pNEZT4- 
encoded minigene are provided, respectively,  by a 0.5-kb BclI-BdI 
fragment from the mouse CD3-8 promoter (52) and a 0.24-kb BclI- 
BamHI fragment containing the SV40 poly(A) site. To prepare 1.3 
mCD3-hCD4c/g,  pNEZT4 was digested with XhoI and then in- 
cubated with Khnow fragment of DNA polymerase I to generate 
blunt ends. This linear plasmid was then digested with NotI to 
release a fragment containing the mCD3-hCD4-SV40 sequences. 
A second 1.3 subclone (pBlueseript 1.3 KV) was prepared that con- 
tains the Khnow fragment-treated  SphI-ClaI fragment inserted 
into the EcoRV site of pBluescript II. The pBluescript 1.3 RV 
plasmid was digested with EcoRI,  blunted by treatment  with 
Klenow fragment,  and then digested with NotI. The final 1.3 
mCD3-hCD4c/g construct was prepared by ligating the XhoI-NotI 
fragment  from  pNEZT4  to  the  EcoRI-NotI  fragment  from 
pBluescript 1.3 RV. 
Preparation of DNA  Fragments  for Microinjection.  Large-scale 
plasmid preparations of transgene constructs were performed ac- 
cording to Sambrook et al. (53). All three constructs were digested 
with XhoI and NotI to release the inserts from vector sequences. 
Digests were fractionated  by electrophoresis  through 0.7% (CD4-1 
and 1.3 CD4-1) or 1.0% (1.3 mCD3-hCD4c/g)  agarose gels. The 
inserts were isolated by one of three methods: (a) electrophoresis 
onto DEAE membranes (Schleicher  & Schuell, Inc., Keene, NH) 
and purification according to the instructions  provided by the 
manufacturer, followed by CsC1 density gradient centrifugation 
(54) and ethanol precipitation; (b) by excision of a gel slice con- 
taining the insert and electrophoresis of the DNA fragment into 
0.Sx Tris-borate-EU~ buffer (53) contained  within dialysis  tubing, 
followed by CsCI density gradient centrifugation  and ethanol 
precipitation; or (c) by PFGE, excision of the gel slice, and elec- 
troehtion of the insert, followed by phenol extraction and two 
rounds of ethanol precipitation (51). DNA pellets were washed in 
70% ETOH and then resuspended in deionized H20 and diluted 
to a concentration of 2-8 #g/ml with lx  injection buffer (54). 
Transgenic Mice.  The human CD4 transgene constructs were 
microinjected into fertilized eggs from (C57B1/6 x  CBA/CA)F1 
matings and the injected eggs were transferred to pseudopregnant 
female CD-1 mice (Charles River Breeding Laboratories, Wil- 
mington, MA) for development  to term. Transgenic  founders were 
identified by Southern blot hybridization of HindlII-digested tail 
DNAs to a radiolabeled human CD4 cDNA. 
Northern Analysis.  Total  RNAs from tissues and purified cells 
of CD4-1 and 1.3 CD4-1 transgenic mice were isolated  by the acid- 
guanidinium  thiocyanate-phenol-chloroform extraction  method 
(55). Thymocyte and  splenocyte suspensions were prepared by 
grinding whole thymus and spleen  between two frosted glass slides 
in cold PBS, 1% BSA, and 0.1% sodium azide. Suspensions were 
filtered through Nitex (Tetko, Inc., Elmsford, NY).  RBC were 
lysed in 0.15% NH4C1, 10 mM KHCO3,  0.1 mM EDTA. The 
cells were washed twice in PBS, 1% BSA, and 0.1% sodium azide, 
then resuspended in acid-guanidinium thiocyanate solution, and 
disrupted by expulsion through an 18-gauge needle. B cells were 
depleted from splenocyte suspensions using nylon wool columns 
(Polysdences  Inc., Warrington, PA; 56). The effadency  of the deple- 
tions was determined by FACS  |  analysis  (Becton Dickinson & Co.) 
of aliquots of B cell-depleted splenocytes  (see below). Depletions 
removed 93-97%  of all B220  + splenocytes. 15/~g of total RNA 
was subjected  to electrophoresis  through 1% agarose-formaldehyde 
gels and blotted onto GeneSereen  nylon membranes  (New England 
Nuclear, Boston, MA). Blots were hybridized to either a radiola- 
beled human CD4 cDNA lacking sequences encoding the highly 
conserved cytoplasmic domain, or a radiolabeled 143-bp PstI-PstI 
restriction fragment derived from the 3' untranslated portion of 
the mouse CD4 cDNA (57). Prehybridizations (0.5-1 h)  and 
hybridizations (16-24 h) were performed at 55~  in 0.5x  nylon 
wash, 30% formamide, and 1% BSA. (lx  nylon wash consists 
of 14% SDS, 80 mM NazHPO4.7HzO, and 14 mM Na,EDTA. 
2H20,  pH 7.2; 58). Washes were performed twice, for 20 rain 
each, at 65~  in 0.4x  nylon wash, 0.2x  nylon wash, and 0.1x 
nylon wash. Normalization of RNA amounts in each lane was 
achieved by hybridizing Northern blots with an oligonucleotide 
specific for 28S rKNA (59). 
FACS | Analysis.  Thymocyte and splenocyte  suspensions were 
prepared as described above. Aliquots of 106 cells were stained for 
25 rain at 25~  with combinations of the following mAbs: PE- 
anti-mouse B220 (Pharmingen, San Diego, CA), FITC-anti-mouse 
CD8, PE-anti-mouse CD4, FITC-anti-human  CD4, and biotin- 
anti-human CD4 (Becton  Dickinson & Co.). In cases  where biotin- 
conjugated antibodies were used, stained cells were washed twice 
in  PBS, 1%  BSA, 0.1%  sodium azide and then stained with 
Streptavidin-RED613 (Gibco-BRL, Gaithersburg, MD). After in- 
cubation with antibodies and Streptavidin reagents, cells were then 
washed once in PBS, 0.1% sodium azide and fixed in PBS, 0.1% 
sodium azide, and 1% formaldehyde. Fluorescence intensity was 
measured on a FACScan  |  flow cytometer using FACScan  |  research 
software (Becton Dickinson & Co.) and plotted on a logarithmic 
scale. Between 15,000 and 50,000 cells  were analyzed  per plot. Dead 
cells were eliminated from the analysis  on the basis of forward and 
sideways light scatter. 
Nucleotide Sequence  Analysis.  The sequence of the 1.3-kb SphI- 
ClaI restriction fragment was determined  by dideoxy  sequence anal- 
ysis using reagents provided in the sequence kit (U.S. Biochemical 
Corp., Cleveland, OH) according to instructions provided by the 
manufacturer. SK and KS, primers that anneal to the polylinker 
of pBluescript II plasmid vectors, were purchased from Stratagene. 
Additional internal primers were prepared by the Memorial Sloan- 
Kettering Cancer Center Microchemistry Core Facility. Sequence 
comparisons were performed using Microgenie Sequence  Software 
(Beckman Instruments, Inc., Palo Alto, CA; 60). 
Results 
Design of  Human CD4 Transgene Constructs.  The develop- 
mental cues regulating CD4 gene expression are likely to occur 
exclusively in thymocytes maturing in the presence of thymic 
stromal cells. Therefore, elucidation of the mechanisms re- 
quired for the establishment of the complex pattern of CD4 
expression during thymocyte development may necessitate 
the use of an in vivo system that supports all stages  of T 
cell differentiation. Consequently, we chose to define the c/s- 
acting DNA sequence elements regulating the developmental 
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mice. We have used the human, rather than the mouse, CD4 
gene for these studies, because the human gene and its mRNA 
and protein products can be readily distinguished from those 
of the mouse. 
Three human CD4 transgene constructs were prepared and 
tested for expression in transgenic mice. Restriction maps 
for two of these transgenes, CD4-1 and 1.3 CD4-1, are shown 
in Fig. 1 A. CD4-1 was constructed by ligating together the 
inserts from two genomic X clones. The 5' X clone begins 
at a HindlII site 3.5 kb upstream of the transcriptional initi- 
ation site and ends within the first 1 kb of the third intron. 
The 3' X clone begins within the third intron, ",,2 kb up- 
stream of exon 4, and ends 9.5 kb downstream of exon 10. 
This ligation deleted 18 kb of sequence from the third in- 
tron, but left the other 8 introns and 10 exons intact. Thus 
all human CD4 protein coding sequences are present within 
CD4-1 and the total length of CD4-1 is 35 kb. The second 
transgene construct, 1.3 CD4-1, includes, in addition to the 
CD4-1  sequences,  a 1.3-kb SphI-ClaI restriction fragment 
normally located 6.5 kb upstream of the transcriptional ini- 
tiation site of the human CD4 gene. This fragment contains 
a T cell-specific DNase I hypersensitive site, designated HS4 
(51).  DNase I hypersensitive site mapping experiments re- 
vealed that HS4 was present in chromatin from a number 
of human CD4 + T  cell lines, including Jurkat  and CEM, 
as well as from human PBL depleted of CD8 §  cells.  HS4 
was absent in chromatin from a CD4-  human B cell line, 
Raji, and a CD4 + human macrophage cell line, U937 (51; 
data not  shown). 
The third transgene construct, 1.3 mCD3-hCD4c/g, is di- 
agrammed in Fig. 1 B. 1.3 mCD3-hCD4c/g contains the 1.3 
SphI-ClaI fragment joined to a human CD4 minigene. The 
minigene was prepared by fusing an EcoRI-SacI cDNA frag- 
ment encoding exons 2-4 and part of exon 5 (49) to a genomic 
SacI-BamHI fragment encoding the remainder of exons 5, 
6-9, and part of 10 (D. Grass,  A. Garvin, D. Littman, N. 
Lee, and E. Lacy, manuscript in preparation). The minigene 
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Figure  1.  Map of the human CD4 locus and human CD4 transgene  constructs. (A) The top line shows a restriction  map of the human CD4 genomic 
locus with restriction sites designated as follows: HindlII (H), BamHI (B), EcolLI  (R), SphI (8), and ClaI (C). The SphI and ClaI sites have not 
been completely  mapped. Boxes  indicate  exons 1-10, with stippled  bc~es representing  untranslated regions  and filled  boxes  representing  translated  regions. 
The bold vertical  arrow (H$4) denotes the location of a T ceU-specific  DNase I hypersensitive  site identified  in the chromatin of two human CD4 § 
T cell lines and in the chromatin  of human PBL depleted  of CD8 + T cells. The underlined  region shows the 1.3-kb Sphl-ClaI restriction  fragment 
encompassing HS4 that was used in the generation of two transgene constructs. The middle line shows a restriction map of the CD4-1 transgene 
construct. Diagonal lines between the CD4 locus and the CD4-1 transgene denote the limits of the inserts from two genomic X clones that were 
fused to construct  the CD4-1 transgene. The third line shows a restriction  map of the 1.3 CD4-1 transgene  construct. (B) Map of the 1.3 mCD3-hCD4c/g 
transgene construct. The diagram indicates the five sequence  elements comprising the 1.3 mCD3-hCD4c/g transgene construct. Each of the sequence 
elements is denoted  by a differently  patterned block, as shown beneath the diagram. 
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scriptional initiation and termination signals were provided, 
respectively, by a 0.5-kb BclI-BclI fragment from the mouse 
CD3-~ promoter (52) and a 0.24-kb BclI-BamHI fragment 
containing the SV40 poly(A) site. 
Each of the three transgene constructs was microinjected 
into fertilized eggs derived from matings between (C57B1/6J 
x  CBA/CA)F1  mice.  Founder  mice  were  identified by 
hybridizing Southern blots of HindlII-digested tail DNA to 
a radiolabeled human CD4 cDNA probe. Five founder mice 
were produced with the CD4-1 transgene and transgenic lines 
were obtained from three of these. Two founders that carry 
the 1.3 CD4-1 transgene were generated and bred. Injection 
with the 1.3 mCD3-hCD4c/g transgene yielded 12 lines. 
Human CD4 transgene expression was examined in all lines, 
and all lines carrying a particular transgene exhibited quali- 
tatively similar patterns of human CD4 expression.  Below 
we present data from three lines: CD4-1, no. 74; 1.3 CD4-1, 
no. 1509; and 1.3 mCD3-hCD4c/g, no. 25. These lines were 
chosen because they contain similar numbers of human CD4 
transgenes ("~50 copies). 
Human CIM Expression in the Spleens of  CD4-1 and 1.3 CD4-I 
Transgenic Mice: B  Cell Expression.  To examine the tissue 
specificity of CD4-1 and 1.3 CD4-1 transgene transcription, 
we performed Northern analyses on total RNA isolated from 
kidney, lung, skeletal muscle, brain, liver, testis, ovary, and 
spleen of adult mice. These experiments showed that both 
the CD4-1 and 1.3 CD4-1 transgenes were expressed prefer- 
entially in spleen (data not shown). 1.3 CD4-1-encoded tran- 
scripts were detected only in spleen, indicating that 1.3 CD4-1 
transgene expression  is highly specific for lymphoid tissue. 
In contrast, CD4-1-encoded transcripts were found in brain 
and lung, as well as in spleen.  Subsequent analyses of the 
CD4-1  transgenic mice demonstrated that the presence  of 
human CD4 transcripts in brain and lung most likely resulted 
from expression of the transgene in resident macrophages (51; 
G.  Wong, D.  Grass, D.  Littman, and E.  Lacy, manuscript 
in preparation). 
Fig. 2 compares the expression of the CD4-1 and 1.3 CD4-1 
transgenes in whole spleen and B cell-depleted splenocytes. 
Lane 1 contains total spleen RNA purified from a (C57BL/6 
x  CBA/CA)F1 nontransgenic mouse; the absence of a hy- 
bridization signal indicates that the human CD4 cDNA probe, 
which lacks the highly conserved cytoplasmic region, does 
not crosshybridize to mouse CD4 transcripts. Both the CD4-1 
and 1.3 CD4-1 transgenic mice were found to express full- 
length 3-kb human CD4 transcripts in whole spleen (Fig. 
2,  top,  lanes 2  and 4).  However,  CD4-1  spleens expressed 
markedly more of the transgene than did 1.3 CD4-1 spleens. 
Interestingly, no human CD4 transcripts were detected in 
the B cell-depleted splenocytes prepared from CD4-1 mice 
(Fig. 2, top, lane 3). In contrast, hybridization of the human 
CD4 cDNA probe to RNA isolated from whole spleen or 
from B cell-depleted splenocytes  of 1.3 CD4-1 mice (Fig. 
2, top, lanes 4 and 5) produced bands of approximately equal 
intensity. Reprobing the Northern blots in Fig.  2 with an 
oligonucleotide specific for 28S ribosomal KNA showed that 
the whole spleen lanes contained about twofold more RNA 
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Figure  2.  (~p) Northern blot analysis of human CD4 expression in 
whole spleen from a (C57B1/6  x  CBA/CA)F1 control mouse (lane 1), 
a CD4-1 transgenic mouse (lane 2), and a 1.3 CD4-1 transgenic mouse 
(lane 4), and in B cell-depleted  splenocytes from a CD4-1 transgenic mouse 
(lane 3) and a 1.3 CD4-1 transgenic mouse (lane 5). The probe used for 
hybridization is a human CD4 cDNA that lacks the sequences encoding 
the highly conserved cytoplasmic region. (Bottom) Autoradiogram of the 
blot shown (top) after hybridization to a radiolabeled oligonucleotide  probe 
specific for the 28S rRNA. All lanes derive from the same gel and autora- 
diogram and were repositioned for the figure. 
than the B cell-depleted spleen lanes (Fig. 2, bottom). Thus, 
the human CD4 transcripts were, in fact, slightly enriched 
in the B cell-depleted splenocytes isolated from the 1.3 CD4-1 
mouse. These results suggest that the CD4-1 transgene is 
transcribed primarily in splenic B cells, whereas the 1.3 CD4-1 
transgene is transcribed predominantly  in a non-B cell popu- 
lation,  most likely  splenic T  cells. 
To confirm our conclusions from the Northern assays, we 
examined the cell surface expression of human CD4 by FACS  | 
analyses of  purified splenocytes. Hg. 3 shows two-color FACS  | 
profiles of  individual CD4-1 and 1.3 CD4-1 mice, after staining 
with anti-human CD4 and anti-mouse B220 antibodies. The 
B220 antigen is expressed on both pre-B and B lymphocytes 
(61), and therefore served as a B cell marker in this experi- 
ment. Both animals  contained similar  numbers of human 
CD4-expressing splenocytes: 18% for the CD4-1 mouse and 
15%  for the 1.3 CD4-1 mouse. As indicated in the upper 
right quadrant, 13% of the CD4-1 splenocytes, but only 2% 
of the 1.3 CD4-1 splenocytes, costained with the anti-human 
CD4 and anti-mouse B220 antibodies.  Thus,  73%  of the 
human CD4 + splenocytes  stained  as B cells in the CD4-1 
mouse, whereas only 12% of the human CD4 + splenocytes 
stained as B cells in the 1.3 CD4-1 mouse. Table 1 docu- 
ments human CD4 and B220 staining in four animals from O  p. 
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Figure  3.  Human CD4 and mouse B220 cell surface expression on 
splenocytes isolated from a CD4-1 and a 1.3 CD4-1 transgenic mouse. 
For each sample,  a total of 50,000 cells was analyzed  by FACS  O. The number 
in each quadrant is the percentage, rounded to the nearest whole number, 
of gated cells falling in that quadrant. Values for the human CD4 § quad- 
rants were corrected for background staining by subtracting values ob- 
tained in those quadrants in a nontransgenic control mouse. Fluorescence 
intensity is indicated on a logarithmic scale. 
each of the CD4-1 and 1.3 CD4-1 lines. These data substan- 
tiate the findings from the individual animals shown in Fig. 
3;  on  average,  78%  of the  human  CD4 +  splenocytes  in 
CD4-1  mice  and  14%  of the  human  CD4 +  cells  in  1.3 
CD4-1  mice were B cells.  When the percentage of human 
CD4 +  cells  that  express  B220  is  normalized  to  the  per- 
centage  of B220 +  cells  in  each  mouse,  there  is  a  sixfold 
reduction of human CD4 expression on B cells in 1.3 CD4-1 
mice compared with CD4-1 mice (0.26/1.6; see Table 1). These 
results suggest that the 1.3-kb SphI-ClaI fragment significantly 
inhibits the inappropriate expression of the CD4-1 transgene 
in  splenic B  cells. 
Haman CD4 Expression in the Spleens of  CD4-1 and 1.3 CD4-1 
Transgenic Mice: T Cell Expression.  Human CD4 expression 
on the CD4 + and CD8 + peripheral T  cell subsets was ex- 
amined in both the CD4-1  and  1.3 CD4-1 transgenic lines 
by three-color FACS  |  analysis. Splenocyte suspensions were 
prepared from four 6-11Ywk-old animals in each line; these 
cells were stained with anti-mouse CD4, anti-mouse CD8, 
and anti-human CD4 antibodies, and then subjected to flow 
cytometric analysis. Fig. 4 A  shows the mouse CD8 vs. mouse 
CD4,  mouse  CD8  vs.  human  CD4,  and  mouse  CD4  vs. 
human  CD4  staining  profiles  from  single,  representative 
CD4-1 and 1.3 CD4-1 transgenic mice. The findings from 
these animals,  and from three other  mice in each line,  are 
compiled in Table 2.  As demonstrated  by both  the mouse 
CD4/CD8  plots  (Fig.  4  A,  top,  and Table 2),  neither  the 
CD4-1 nor the 1.3 CD4-1 transgene altered the percentages 
or  ratios  of single-positive  CD4 +  and  CD8 +  splenocytes 
from  those  observed in  control  mice  (22.1  •  4%  CD4 + 
and 10.1  _+  2.1% CD8+). The mouse CD8 vs. human CD4 
staining  profiles  (Fig.  4  A,  middle)  showed  virtually  no 
detectable human CD4 staining on the CD8 + T  cell subset 
in either the CD4-1 or the 1.3 CD4-1 transgenic mouse. In 
contrast,  the mouse CD4 vs. human CD4 plots (Fig.  4 A, 
bottom) indicated that both the CD4-1 and 1.3 CD4-1 trans- 
genes were expressed on the mouse CD4 + T  cell subset. 4% 
of CD4-1  and 11%  of 1.3 CD4-1  splenocytes costained for 
both mouse and human CD4. These data (Fig. 4  and Table 
2) dearly demonstrate that both human CD4 transgenes are 
preferentially  expressed  in  CD4 +  cells  relative  to  CD8 + 
cells. 
In the experiment presented in Fig. 4 A, 13% of the spleno- 
cytes from the CD4-1 mouse and 11% from the 1.3 CD4-1 
Table  1.  Summary of Human CD4 Expression on Splenic B  Cells in CD4-1 and 1.3 CD4-1 Transgenic Mice 
Percent human CD4 + 
Percent human  Percent human CD4 +  that  are B220 § / 
Sample no.  CD4 §  that are B220 +  Percent B220 §  percent B220 § 
CD4-1 
1.3  CD4-1 
2883  1.93  82.1  57.8  1.4 
3061  22.7  76.4  45.8  1.7 
3062  20.3  78.9  53.0  1.5 
2884  17.2  73.3  42.7  1.7 
Average  19.9  +  2.3  77.7  _+  3.7  49.8  +  6.9  1.6  _+  0.15 
2896  16.6  12.2  52.5  0.23 
2900  13.5  19.2  56.8  0.34 
3066  15.0  12.2  58.5  0.21 
3067  15.7  13.8  52,6  0.26 
Average  15.2  _+  1.3  14.4  +  3.3  55.1  x  3.0  0.26  _+ 0.06 
Splenocytes from four CD4-1 and four 1.3 CD4-1 transgenic mice were analyzed by flow cytometry for cell surface expression of human CD4 and 
mouse B220. Averages for each column are provided along with SD. Four nontransgenic control mice gave values for percent B220 + cells of 64.6, 
67.4,  53.9, and 43.5 (average, 57.4  +_  10.9%).  The FACS  |  profiles for mice 2884 and 3066 are presented in Fig. 3. Discrepancies between the 
percentages shown in Fig. 3 and here result from rounding the percentages to the nearest whole number in Fig. 3 and to the first decimal place here. 
1348  Subclass-specific  Expression of a Human CD4 Transgene Table  2.  Summary of Human  CD4 Expression on Splenic T  Cells from CD4-1 and 1.3 CD4-1 Transgenic Mice 
Percent  human  Percent human 
CD4 §  that  CD4 §  that 
Percent  Percent  human  Percent  Percent  human  Percent  are mCD8 § /  are mCD4 § / 
Sample  human  CD4 §  that are  mouse  CD4 + that are  mouse  percent  mouse  percent mouse 
no.  CD4 §  mouse CD8 +  CD8 +  mouse CD4 +  CD4 +  CD8 §  CD4 + 
CD4-1 
1.3  CD4-1 
2883  15.1  16.7  14.0  25.6  16.7  1.2  1.5 
3061  12.8  4.8  10.2  27.0  22.6  0.47  1.2 
3062  11.3  3.1  7.0  30.1  17.9  0.44  1.7 
2884  8.4  6.7  10.7  28.6  15.5  0.62  1.8 
Average  11.9  +  2.8  7.8  _+  6.1  10.5  +  2.9  27.8  +  2.0  18.2  _+  3.1  0.6  _+  0.35  1.5  _+  0.26 
2896  14.8  2.9  8.7  97.8  24.6  0.33  4.0 
2900  10.0  2.2  8.1  95.3  18.9  0.27  5.0 
3066  10.8  0.8  7.4  97.7  19.3  0.11  5.1 
3067  11.2  0.8  5.4  100  22.7  0.15  4.4 
Average  11.7  _+  2.1  1.7  +  1.1  7.4  _+  1.4  97.7  +  1.9  21.4  +  2.7  0.22  +_ 0.1  4.6  _+ 0.52 
Splenocytes from four CD4-1  and four 1.3 CD4-1 transgenic mice were analyzed by flow cytometry for cell surface expression of human CD4, 
mouse CD4, and mouse CD8. Averages for each column are provided along with SD. Four nontransgenic control mice gave values for percent 
mouse CD4 + cells of 19.8, 23.1, 27.3, and 18.3 (average, 22.1  +  4.0%) and for percent mouse CD8 § cells of 7.0, 10.9, 11.3, and 11.3 (average, 
10.1  +  2.1%).  The FACS  |  profiles for mice 3061 and 3066 are presented in Fig. 4 A, and those for mice 3062 and 2896 are in Fig. 4B. Discrepancies 
between the percentages shown in Fig. 4 and here result from rounding  the percentages to the nearest whole number in Fig. 4 and to the first 
decimal place here. 
mouse expressed human  CD4 (bottom).  Notably,  all of the 
human CD4 + cells in the 1.3 CD4-1  mouse also expressed 
mouse CD4.  However, only 31% of the human CD4 § cells 
in the CD4-1 mouse coexpressed mouse CD4, and 8% stained 
as mouse CD8§  the remaining 61%  stained as non-T cells 
and are presumably B cells. Thus, as previously indicated by 
Northern analyses (Fig. 3), expression of the 1.3 CD4-1 trans- 
gene is quite  T  cell restricted  relative to the  expression  of 
the CD4-1  transgene.  The CD4 + subclass specificity of the 
CD4-1 and 1.3 CD4-1 transgenes, as well as the T  cell spec- 
ificity of the  1.3  CD4-1  transgene,  are demonstrated  more 
clearly when  human CD4 +  splenocytes are assayed for the 
expression of CD4 and CD8 (Fig. 4 B). Both transgenes ex- 
hibited significant T  cell expression exclusively in the CD4 § 
subset.  Furthermore,  while  the  vast  majority  of human 
CD4 § cells in the 1.3 CD4-1 mice stained as T  cells (mouse 
CD4+CDS-),  most of the human CD4 + cells in the CD4-1 
mouse  stained  as non-T  cells  (mouse  CD4-CDS-). 
These data argue that sequence elements within the CD4-1 
construct are sufficient to direct transgene expression prefer- 
entially to the CD4 §  subset of peripheral T  cells,  albeit to 
only a small percentage of the CD4 + cells. The data also re- 
veal that the 1.3-kb SphI-ClaI fragment enhances the CD4 + 
subset-specific expression of human CD4 in 1.3 CD4-1 trans- 
genic splenocytes. This enhancement is manifested as an in- 
crease in  the  number  of mouse CD4 +  cells  that coexpress 
human CD4 in the 1.3 CD4-1 mice compared with that in 
the CD4-1 animals. However, since CD4-1-encoded transcripts 
were not detected in B cell-depleted splenocytes (Fig. 2, top), 
it is likely that the 1.3-kb SphI-ClaI fragment is also enhancing 
the levels of human  CD4  transcripts  per cell.  In addition, 
the Northern and FACS  |  analyses show that the 1.3-kb SphI- 
ClaI fragment can confer a T  cell specificity on the relatively 
B  cell-specific CD4-1  transgene. 
Human CD4 Expression in the Thymuses of CD4-1 and 1.3 
CD4-1  Transgenic Mice.  To assess whether the CD4-1  and 
1.3 CD4-1 transgenes can direct human CD4 expression to 
the thymus, we hybridized a radiolabeled human CD4 cDNA 
probe to Northern  blots of total RNA,  extracted from ei- 
ther whole thymus or isolated thymocytes. The results are 
shown  in  Fig.  5,  top.  Lane  I  contains  total  thymus  RNA 
purified  from  a  (C57BL/6  ￿  CBA/CA)F1  nontransgenic 
mouse; as in the Northern of the splenic KNAs, the absence 
of a hybridization signal indicates that the human CD4 cDNA 
probe did not crosshybridize to mouse CD4 transcripts. Full- 
length human CD4 transcripts were detected in whole thymus 
RNA prepared from either a CD4-1 (lane 2) or a 1.3 CD4-1 
mouse (lane 4),  demonstrating  that the  thymus is a major 
site of transcription for both transgenes. However, a hybrid- 
ization  signal was barely detectable in RNA  isolated from 
purified  CD4-1  thymocytes (lane 3),  whereas  a  significant 
enrichment of human CD4 transcripts was observed in purified 
1.3 CD4-1 thymocytes (lane 5). A duplicate of the Northern 
shown in Fig. 5, top, was hybridized to a mouse CD4 probe, 
and the resulting autoradiogram, displayed in Fig. 5, bottom, 
showed  a similar enrichment  of mouse CD4  transcripts  in 
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Figure  4.  (A) Human CD4, mouse CD4, and mouse CD8 cell surface 
expression on splenocytes  from a CD4-1 and a 1.3 CD4-1 transgenic mouse. 
For each sample, a total of 15,000 cells was analyzed by three-color FACS  ® 
analysis.  The number in each quadrant  is the percentage, rounded to the 
nearest whole number,  of gated cells falling in that quadrant.  Values for 
the human  CD4 + quadrants  were corrected for background  staining by 
subtracting values obtained in those quadrants in a nontransgenic control 
mouse. Fluorescence intensity is indicated on a logarithmic scale. (B) Mouse 
CD4 and mouse CD8 cell surface expression  on  human  CD4 + spleno- 
cytes from  CD4-1  and  1.3  CD4-1  transgenic  mice. 
isolated  thymocytes relative  to whole thymus in both the 
CD4-1 and 1.3 CD4ol mice. These findings suggest that the 
human CD4 expression  detected in the 1.3 CD4ol mouse 
resulted primarily  from transgene  transcription  in thymic T 
Figure  5.  Northern  blot analysis  of total R.NA isolated from whole 
thymus of a (C57B1/6  x  CBA/CA)FI control mouse (lane I), a CD4-1 
transgenic mouse (lane 2),  and a  1.3 CD4-1  transgenic mouse (lane 4), 
and from purified thymocytes of a CD4-1 transgenic mouse (lane 3) and 
a  1.3  CD4-1  transgenic  mouse  (lane 5).  (%F) The hybridization  probe 
was a human CD4 cDNA clone that lacks the highly conserved cytoplasmic 
region.  (Bottom) The hybridization probe is a mouse CD4 cDNA clone 
derived from the 3' untranslated  region, which is not well conserved be- 
tween the mouse and human CD4 genes. Hybridization of the two blots 
to an oligonucleotide specific for 28S ribosomal RNA indicated that  all 
lanes contained an equivalent amount of RNA (data not shown). All lanes 
derive from the same gel and autoradiogram  and were repositioned for 
the figure. 
cells. In contrast,  the human  CD4 expression  observed in 
the CD4-1 mouse appears to have derived from transcription 
in a non-T component of the thymus, possibly a bone mar- 
row-derived component of the thymic stroma (51; G. Wong, 
D. Grass, D. R. Littman, and E. Lacy, manuscript  in prepa- 
ration). 
We performed FACS  ® analyses on thymocytes isolated from 
CD4-1  and  1.3  CD4-1  transgenic  mice  to  confirm  the 
Northern data and to examine the expression of the human 
CD4 transgenes in the different thymocyte subsets. Suspen- 
sions of thymocytes from 6-10-wk-old mice were stained with 
anti-mouse CD4, anti-mouse CD8, and anti-human  CD4 
antibodies and subjected to flow cytometric analysis. Repre- 
sentative  FACS  ® profiles  from  individual  CD4-1  and  1.3 
CD4-1 mice are shown in Fig. 6 A. Fig. 6, top and middle, 
shows the mouse CD4/CD8 staining  profiles, which indi- 
cated that  the CD4ol and  1.3 CD4-1 transgenic  mice had 
normal numbers  and ratios of the CD4- CD8- double-neg- 
ative,  CD4 +  CD8 + double-positive,  and  CD4 ÷  CD8-  and 
CD4- CD8 + single-positive  thymocytes.  Control  animals 
contained  4.2  +  0.64%  double-negative,  73.9  _+  5.3% 
double-positive,  17.3  _+  5.4% CD4 single-positive, and 4.7 
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Figure 6.  (A) Human CD4, mouse 
CD4, and mouse CD8 cell surface ex- 
pression on thymocytes from a CD4-1 
and a 1.3 CD4-1 transgenic mouse. A 
total of 15,000 cells was examined by 
three-color FACS  |  analysis for each 
sample. The number in each quadrant 
is the percentage, rounded to the nearest 
whole number, of gated cells falling in 
that  quadrant.  Values for  human 
CD4 + quadrants were corrected for 
background  staining by  subtracting 
values obtained in those quadrants in 
a nontransgenic  control mouse. Fluores- 
cence intensity  is denoted on a logarith- 
mic scale. (B) Human CD4 expression 
on gated mouse CD8 single- positive 
thymocytes  (top) and gated mouse CD4 
single-positive  thymocytes  (bottom)  from 
the 1.3 CD4-1 transgenic  mouse shown 
in  A.  Horizontal  bars delimit the 
human CD4-negative thymocytes (1) 
and the human CD4 positive thymo- 
cytes (2). The percentage  of  cells falling 
within the limits of  2 are indicated  above 
the bar. Fluorescence intensity is de- 
noted on a logarithmic  scale (C) Mouse 
CD8  and  mouse  CD4  cell surface 
expression on  gated  human  CD4 + 
thymocytes  from the 1.3 CD4-1 trans- 
genic mouse shown in A. 
+  2.5%  CD8 single-positive thymocytes. Consistent with 
the Northern results in Fig.  5,  no human CD4 expression 
was detected on either the mouse CD4 + or CD8 + thymo- 
cytes of the CD4-1 mouse (Fig. 6 A, bottom and middle left, 
respectively). The 1.3 CD4-1 transgenic mouse, on the other 
hand, exhibited human CD4 expression on 44% ofaU thymo- 
cytes. 77% of the human CD4 § thymocytes costained with 
mouse CDS;  98%  costained with mouse CD4  (Fig.  6 A, 
middle and bottom right). 
The FACS  |  profiles shown in Fig.  6 A  indicate that the 
1.3 CD4-1 transgene must be expressed on at least some of 
the double-positive thymocytes. To determine the distribu- 
tion of human CD4 expression on the CD4 and CD8 single- 
positive thymocyte subsets in the 1.3 CD4-1 mice, we plotted 
histograms of human CD4 fluorescence for the CD4-CD8 + 
and CD4 + CDS-  cells.  Fig. 6 B, top, shows the profile from 
one representative mouse and reveals that only 5% of mouse 
CD8 single-positive thymocytes express human CD4. In con- 
trast, Fig. 6 B, bottom, shows that 47%  of the mouse CD4 
single-positive thymocytes stain for the human CD4 trans- 
gene. Thus, the subclass-specific expression of the 1.3 CD4-1 
transgene observed on splenic T  cells is also evident on ma- 
ture thymocytes. Histograms of human CD4 fluorescence were 
also plotted for the CD4-CD8 §  and CD4§  -  thymo- 
cytes of CD4-1 mice, and no mature single-positive thymo- 
cytes were found that expressed human CD4 (data not shown). 
Fig.  6  C  presents the mouse CD4/CD8  staining profile of 
the  human  CD4 +  thymocytes from  the  same  1.3  CD4-1 
transgenic  mouse shown  in  Fig.  6 B.  78%  of the human 
CD4 +  cells fall into  the double-positive subset,  and  20% 
into the CD4 single-positive subset. The double-negative and 
CD8 single-positive thymocytes largely failed to express human 
CD4.  Thus,  the pattern of expression of the human CD4 
transgene is identical to that of mouse CD4. Similar findings 
were obtained from three other 1.3 CD4-1 transgenic mice, 
and these are summarized in Table 3. These data indicate that 
the CD4-1  transgene lacks the sequences required to drive 
CD4 expression in either immature or mature thymocytes 
and that the 1.3-kb SphI-ClaI fragment provides CD4-1 with 
the missing information needed to fully recapitulate the stage 
and  subclass-specific expression of CD4  in the thymus. 
Transgene Expression in  1.3  mCD3-hCD4c/g  Transgenic 
Mice.  To evaluate the contribution that the 1.3-kb SphI-ClaI 
fragment makes to the subclass-specific expression of the 1.3 
CD4-1 transgene, we produced transgenic lines carrying the 
1.3 mCD3-hCD4c/g  construct  (Fig.  1 B).  In  1.3  mCD3- 
1351  Blum et al. Table  3.  Summary of Human CD4 Expression on Thymocytes of 1.3 CD4-I  Transgenic Mice 
Percent human  Percent human  Percent human 
Percent  human  CD4 + that are  CD4 + that  are  CD4 + that  are 
Percent  human  CD4 §  that  are  mCD8  single  mCD4 single  double 
Sample no.  CD4 §  double positive  positive  positive  negative 
2896  51.1  85.1  0.53  13.5  0.86 
2900  42.5  88.0  1.2  9.6  1.2 
3066  43.4  78.2  0.93  20.1  0.79 
3067  37.6  84.0  1.0  13.4  1.7 
Average  43.7  _+  5.6  83.8  +  4.1  0.91  _+  0.3  14.2  _+  4.4  1.2  _+  0.4 
Thymocytes from four CD4-1 and four 1.3 CD4-1 transgenic mice were analyzed by flow cytometry for cell surface expression of human CD4, 
mouse CD4, and mouse CD8. Averages for each column are provided along with SD. Four nontransgenic control mice gave values for percent 
mouse CD4 single-positive cells of 16.8, 23.6, 18.3, and 10.6 (average, 17.3 _+ 5.4%);  for percent mouse CD8 single-positive cells of 1.6, 4.7, 
4.5,  and 7.8 (average, 4.7  _  2.5%);  for percent mouse CD4*CD8 + cells of 78.1, 67.0, 72.4, and 77.9 (average, 73.9  _+ 5.3%);  and for percent 
mouse CD4-CDS-  cells of 3.6,  4.7,  4.8, and 3.7 (average, 4.2  _+ 0.64%).  The FACS  |  profiles for mice 3061 and 2900 are presented in Fig. 6 
A, and those for mouse 3066 in Fig. 6 B, and C. Discrepancies  between the percentages shown in Fig. 6 and here result from rounding the percentages 
to the nearest whole number in Fig. 6 and to the first decimal place here. 
hCD4c/g,  the human CD4 promoter has been replaced by 
the mouse CD3-~ promoter and a number of other human 
CD4  genomic  sequences  have been  deleted:  the  5'  and  3' 
flanking sequences present in CD4-1,  exon  1,  introns  1-4, 
and the untranslated  portion of exon  10.  In six transgenic 
lines that carry a control mCD3-hCD4c/g transgene, which 
lacks the  1.3-kb SphI-ClaI fragment,  human  CD4 was ex- 
pressed on all subsets of T  cells (M.  Blum and E. Lacy, un- 
published  results).  Thus,  no  inherent  CD4 +  cell  subclass 
specificity is encoded by the mouse CD3-/J promoter and the 
CD4 sequences included in the cDNA/genomic hybrid gene. 
Splenocytes from adult 1.3 mCD3-hCD4c/g transgenic mice 
were stained with anti-mouse CD4,  anti-mouse CD8, and 
anti-human CD4 antibodies and examined by flow cytometric  o 
analysis.  As  shown  in  Fig.  7,  both  the  mouse  CD8 §  and  E 
CD4 + splenocyte subsets expressed the human CD4 trans- 
gene. Similarly, both CD4 and CD8 single-positive thymo- 
cytes, as well as double-positive thymocytes, expressed human 
CD4 (data not shown). Thus, the 1.3-kb SphI-ClaI fragment 
appears incapable,  on its own,  of restricting  transgene  ex- 
pression specifically to the CD4 +  subsets of immature and  co 
mature T  cells. Fig. 7, middle and bottom, reveals that >90%  0 
of the splenocytes in the  1.3 mCD3-hCD4c/g  mouse were  E 
stained by the  anti-human  CD4  antibody,  indicating  that 
most B cells also express the human CD4 transgene. Expres- 
sion of the transgene in B cells was confirmed by three-color 
FACS  |  analyses using anti-B220, anti-CD3, and anti-human 
CD4 antibodies (data not shown). These data argue that the 
1.3-kb SphI-ClaI fragment alone cannot inhibit transgene ex- 
pression in B  cells.  Therefore,  the T  cell-restricted  expres-  ,:r 
sion  of the  1.3  CD4-1  transgene  may have been mediated 
by an interaction  between  the  SphI-ClaI fragment  and  se-  E 
quences within CD4-1 that are absent in 1.3 mCD3-hCD4c/g. 
Nucleotide Sequence of the 1.3-1eb SphI-ClaI Fragment Reveals 
Homology  to a Mouse  CD4 Enhancer.  We  determined  the 
nucleotide sequence of the 1.3-kb SphI-ClaI fragment (Fig. 
8 A) and compared it with the 772-bp sequence reported by 
Sawada and Littman  (62)  for a mouse CD4 enhancer.  The 
772-bp mouse sequence is located "~13 kb upstream from the 
transcriptional start site of the mouse CD4 gene; it was shown 
to provide T cell-specific enhancer activity by transient trans- 
fection assays using a chloramphenicol acetyl transferase (CAT) 
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Figure 7.  Human CD4 cell surface  ex- 
pression on splenocytes  from a 1.3 mCD3- 
hCD4c/g  transgenic mouse. A total of 
15,000 cells was analyzed  by flow cytom- 
etry. The number in each quadrant is the 
percentage, rounded to the nearest whole 
number, of gated cells falling  in that quad- 
rant. Values for human CD4 + quadrants 
were corrected for background staining 
by subtracting the values obtained in those 
quadrants  of a  nontransgenic  control 
mouse. Fluorescence intensity is denoted 
on a logarithmic scale. 
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CACCTGTGGTCCTAGTTATTCAGGAGGCTGAGGGAGAAGAATCACTGGAG  50 
GCTAGGATTTCCAGGCTGTAGTGAGCCATGATTGTGCTATTTCACTCCAG  100 
CTTGGGTGACAGGGTGAGATCCTGTGTCTAA~T~TA~TAAT  150 
AATAAACATTATCTCACACAACGAGGAATCCAGGAGCAGTCTTGCTGAGT  200 
AGTTCTGGCACAGGGTTGCTCATGAGGTTGCTGCTGAGGTGAGGGTCAGG  250 
TCTGGAGCCATCTGAAGGCTGGGATGGGGCTGGAGATTCTGCCTCCAAGA  300 
CAGCTCACTCGGGAGGCTGTCGGCCAGAGGCTTAACTCCTCCCTGTGTGG  350 
GTGTCTTTATGGGGCCTCTCACAACACGACACAGCAACTGGCTTCCCCCA  400 
GAGGACAGCGTGGAAAAGACAAAAGCTACCACATCTTTATTTCAAGATTA  450 
GATTTGATCTTGAAAGCAACGTGCCATAATTTCTGCCCTATTCTATTGAT  500 
CACAGAGACCAACCTGGTGCAAGCAGGAGGGGGCAATGCAAGGGTGTGAA  550 
CTGAGGGAGACAGGAGTCACTGGGGGCCATCTTGCAGCCTGGCTGTCAGA  600 
GTGGGGAGCAGTGCCTGAAACAGAGATAGGCCAAGAGACGGGAAGGGACG  650 
TCTCTGAGCATCTCCATCCCCAGCCCTCTTCTCTTGTCCACTCTCCAGAA  700 
GTTCTGGAAGCCAAGTGAGGTCCAGGGCCTTGGCAAGTCGAGTGTGTGAG  750 
GTAGGAGGCGATACTGTGCACATTCAGCCTTGGAGTCGGGTTTGCCAGCG  800 
GTTCCCCTGACCCCTACGTGGTCTTCTCAGCTCCATAGTGCAGAGGAGGA  850 
GCCTCTGCAGGCCCAGAAATTTCCCTGCCCACCTCCCCTACCAGGTAGAG  900 
ATGTTAGGGTTCAGGCCTGAGCCCCTGCTGCTATCCCTCCTTCAAAGGAG  950 
GAGATCAAGGAGCTTAGGGTCCCCCGCACAC, GCCACCCC.AGGGTGGC~"TT  i000 
CTTCCTTTGAAGGGAATTGCTTTGGGGTC~.,GGTCGGTTCTATCTGCTCAC  1050 
TCTGTGGCTGACAGTTTCTCCAAGGGGCTC,~]~~CTC~C,C  II00 
CCGGGCTGAGCTCTGAAACGTGCCTACTCAAACTTCCCGTGGGGTAGGGG  1150 
AGGCCCAGAACCACCCTCTGAGAGTGGCAAARAGTGGTCCTGGAGCCAGG  1200 
GGAAATGTGGATGGGGTAGAGATGGCATC  1229 
B 
132  158 
AAAGAATAATAACAATAATAATAAACA 
******  **  **  **  **  **  ****  74% 
MOUSE  ~GAACA 
42  68 
325  356 
HEMKN  CAGAGGCTTAACTC  CTCCCTGTGTGGGTGTCT 
***  ***  ***  ***  **  ***  **  *  61% 
MOUSE  CAG  CTTTGCTCTCTCTGTGGCTGGCAGTTT 
155  184 
902  926 
HDMAN  TGTT  AGGG TTCAGGCCTGAGCCCCT 
****  ****  ****  *  **  **  ***  69% 
MOUSE  T~ITTTACAGGGCTTCATGGCTCAGAACCT 
-43 
978  1001 
HUMAN  ACAGGCC  ACC  CCAGGGTG  GGG TTC 
***  **  ***  ***  ****  ***  ***  66% 
MOUSE  A_  ~i  TC  CC  CAACCAA GC  CAAGGTGTTG GGGTTIC  I 
1021  1049 
HUMAN  TTTGGGGTGGGGTCGGTTCTATCTGCTCA 
**  ***  ***  *  ***  **  ***  ***  69% 
MOUSE  TTGGGG  TGGAGGCGGATC  CTG  TCA 
134  157 
1043  1077 
HUMAN  CT  GCTCACTCTGTGGCTGACAGTTTCTCCAAGGGG 
**  ****  ***********  ************  ***  86% 
MOUSE  CTTTGCTCTCTCTGTGGCTGGCAGTTTCTCCAAAGGG 
159  195 
1059  1085 
HUMAN  TGACAGTTTCTCCAAGGGGCTGC  AGGT 
**  ***  ***  *****  **  **  ****  75% 
MOUSE  TG  CAGCTTC  CAAGGTGCCGCCAGGT 
348  372 
1081  1127 
HUMAN  CAGGTGTCAGCTGTCTGAGCCCGGGCTGAGCTCTGAAACGTGCCTAC 
*************  *******  ******  *  ****  **  **  ****  83% 
MOUSE  CAGGTGTCAGCTGGCTGAGCCTAGGCTGAACCCTGAGACATG  CTAC 
199  247 
1096  1118 
HUMAN  TGAGCCCGGGCTG  AGCTCTG  AAA 
*******  ****  ***  **  ***  71% 
MOUSE  TGAGCCCCAGCTGTTAGCCCTCTGCAAA 
17  44 
1176  1204 
HUMAN  GGCAAAAAGTGGTC  CTGG  AGCCAGGG  GAA 
***  **  **  ***  ****  ****  **  ***  61% 
MOUSE  GGGTAACAGGTGTCAGCTGGCTGAGCCTAGGCTGAA 
193  228 
1201  1229 
HUMAN  GGAAATGTGGATGGGGTAGAGATGGCATC 
**  *  **  **  ******  ***  **  ***  72% 
MOUSE  GGGAGTGGGGTTGGGGTGGAGGCGG  ATC 
124  151 
Figure 8.  (.4)  Nudeotide  sequence  of the 1.3-kb SphI-ChI human CD4 
genomic fragment encompassing HS4. Numbers to the fight of each line 
of sequence refer to the last nucleotide  in each line. Regions of homology 
with the mouse  CD4 enhancer  (numbered  according  to Sawada  and Littman 
[62]; Genbank accession number M75688) are indicated in boldface. Two 
consensus binding sites for basic helix-loop-helix  proteins are underlined. 
reporter gene driven by the mouse CD4 promoter (62). In- 
terestingly,  a 339-bp minimal enhancer fragment, defined by 
the transient transfaction experiments, functioned equally well 
in CD4 + and CD8 + T cell lines (62). Sequence comparison 
identified 11 regions of the 1.3-kb SphI-ClaI  fragment that 
share homology with the 772-bp sequence of the mouse CD4 
enhancer;  these are shown in boldface in Fig. 8 A  and are 
aligned with the mouse sequence in Fig. 8 B.  Each of the 
11 regions spans between 27 and 47 bp and shares between 
61 and 86% homology with the mouse sequence. As depicted 
in Fig. 8 A,  most of the homology lies within the 3' ter- 
minal 200-300  bp of the  1.3-kb  SphI-ClaI  fragment. 
DNase I footprint analyses and electrophoretic mobility 
shift assays (EMSA)  identified three nuclear protein binding 
sites  within  the  minimal  mouse  CD4  enhancer  (CD4-1, 
CD4-2,  and CD4-3;  62).  Consensus binding sites for basic 
helix-loop-helix  (bHLH)  proteins,  5'-CANNTG-3',  were 
found in CD4-1 and CD4-3; CD4-1 contains a single bHLH 
motif and CD4-3 contains two tandem motifs, arranged with 
incomplete dyad  symmetry (62).  Mutations  in the CD4-3 
site were shown to reduce enhancer activity by >90% (62). 
CD4-2  was found to contain a consensus binding  site for 
TCF-la (5'-CANAG-3'), a T cell-specific  transcription factor 
known to bind enhancers of a number of T cell-specific genes 
(63). However, mutations in CD4-2 reduced the activity of 
the minimal mouse CD4 enhancer only moderately (62). The 
sequence  of the CD4-3  site is completely conserved within 
the 1.3-kb SphI-ClaI human CD4 fragment and it lies within 
a region (1081-1127)  that exhibits 83% homology with the 
mouse CD4 enhancer.  Another region of the 1.3-kb SphI- 
ClaI fragment  (1176-1204) shows homology (61%) with the 
segment of the mouse CD4 enhancer that includes the CD4-3 
site; however, the CD4-3  site itself is not well conserved in 
the human sequence. A segment of the mouse CD4 enhancer 
that contains the CD4-1 site shares 71% homology with the 
1.3-kb SphI-ClaI  fragment (1096-1118), but the sequence of 
the CD4-1 site is not conserved. We also identified a number 
of TCF-lc~ consensus sites within the 1.3-kb SphI-ClaI  frag- 
ment, but none of them was located within the areas of ho- 
mology with the mouse CD4 enhancer. Of possible impor- 
tance  is our finding that  the region of greatest  homology 
(86%) does not contain any of the previously defined nuclear 
protein binding sites within the mouse CD4  enhancer.  In 
(/3) Regions of homology between the human CD4 1.3-kb SphI-ClaI re- 
striction fragment (top line) and the mouse CD4 enhancer (bottom line). 
Nucleotides in the top lines are numbered according to the human se- 
quence in A. Nucleotides in the bottom lines are numbered according 
to the mouse sequence recorded under the Genbank accession number 
M75688. The 339-bp mouse  CD4 minimal  enhancer  extends from  nucleo- 
tide 80 to 418 of the Genbank sequence. Asterisks  between the lines indi- 
cate identities. Interruptions  were  introduced to permit optimal  alignment 
of homologous regions. Percentages  to the fight of each sequence  compar- 
ison indicate the amount of sequence identity, as determined using 
Microgenie software  (Beckman  Instruments, Inc.; 60). Nucleotides  within 
the mouse CD4 enhancer that comprise the CD4-3 DNase I footprint 
(62) are indicated  in boldface. Underlined  regions  denote  consensus  binding 
sites for basic helix-loop-helix  proteins. These sequence data are available 
from EMBL/Genbank/DDBJ  under accession number X70672. 
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fragment (902-926 and 1059-1085) that share homology with 
sequences outside of the minimal mouse CD4 enhancer. 
Discussion 
In this study, we have reconstituted the stage and T  cell 
subclass-specific  expression of the CD4 gene in transgenic 
mice. Our findings demonstrate that the developmentally ap- 
propriate expression of a human CD4 transgene depends on 
at least two sets of sequences,  one contained in the 1.3-kb 
SphI-ClaI upstream fragment and one present within the 35-kb 
CD4-1 construct. As shown by the Northern data in Fig. 
5 and the FACS  |  analyses in Fig. 6, CD4-1 transgenes lacking 
the 1.3-kb SphI-ClaI fragment are not expressed in thymo- 
cytes. When this fragment is included in the transgene, human 
CD4 is expressed exclusively on double-positive and CD4 
single-positive thymocytes. Thus, the 1.3-kb SphI-ClaI frag- 
ment appears to be functioning as an enhancer element, and 
we will, therefore, refer to this fragment as the human CD4 
enhancer. 
The differentiation of CD4-CD8-  thymocytes into CD4 + 
CD8 + cells is a regulated transition that depends on the ex- 
pression of the TCR B chain (64).  CD4 transgene expres- 
sion is not detected on the double-negative thymocyte subset 
in  the  1.3  CD4-1  transgenic  mice,  and  is  first  found  at 
significant levels on the double-positive subset.  Therefore, 
the 1.3 CD4-1 transgene is apparently capable of activating 
human CD4 expression at the correct stage of thymocyte de- 
velopment. Since the human CD4 protein can be expressed 
on the surface of CD4- CD8-  thymocytes in the 1.3 mCD3- 
hCD4c/g transgenic mice (M.  Blum and E.  Lacy, unpub- 
lished observations), the absence of the human CD4 protein 
on CD4-CD8-  thymocytes in the 1.3 CD4-1 mice suggests 
that the developmental stage-specific expression of CD4 is 
regulated at the transcriptional level. However, alternate ex- 
planations are possible. For example, the 1.3 mCD3-hCD4c/ 
g-encoded transcript is not identical to the 1.3 CD4-1-en- 
coded transcript.  The former lacks untranslated sequences 
present in exons 1 and 10 of CD4,  as well as introns 1-4. 
Thus, the 1.3 CD4-1 transgene may be transcribed in both 
double-negative and double-positive thymocytes and the stage- 
specific expression of human CD4 on the CD4+CD8 + cells 
achieved by a posttranscriptional mechanism. We have not 
yet  examined  human  CD4  expression  on  multipotential 
hemopoietic bone marrow stem cells and early thymic pre- 
cursor cells, and consequently, we do not know whether the 
1,3 CD4-1 transgene is appropriately expressed on these pro- 
genitor cells. 
The sequence elements that direct 1.3 CD4-1  transgene 
expression specifically to the CD4 +  CD8-  peripheral T cell 
subset appear to reside within the 35-kb CD4-1 construct. 
The FACS  |  analyses presented in Fig. 4 and summarized in 
Table  2  show  that  both  the  CD4-1  and  the  1.3  CD4-1 
transgenes were expressed preferentially on the mouse CD4 
single-positive subset of splenic T cells. The 1.3-kb SphI-ClaI 
fragment enhanced the subchss-specific expression of the CD4- 
1-encoded transgene,  as  evidenced by the increase in  the 
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number of CD4 § CD8-  peripheral T cells that coexpressed 
human CD4 in the 1.3 CD4-1 mice compared with the CD4-1 
mice. Possibly,  the presence of the human CD4 enhancer 
shielded the CD4-1 construct from chromosomal position 
effects that  are  known, to  obstruct  transgene  expression 
(65-68). The 1.3 mCD3-hCD4c/g transgenic mice expressed 
the human CD4 transgene on all subclasses of T cells (Fig. 
7); thus the human CD4 enhancer cannot, on its own, direct 
CD4 subclass-specific expression of a transgene. Consequently, 
the sequences that target human CD4 expression to CD4 + 
CDS-  peripheral T  cells may be contained entirely within 
the CD4-1 construct. Since the CD4-1  transgene was not 
expressed in the thymus, it is unclear whether the same CD4- 
1-encoded sequences that  are sufficient for CD4  subclass- 
specific expression in peripheral T cells are also required for 
CD4 subclass-specific expression of the 1.3 CD4-1 construct 
in thymocytes. 
A comparison of the 1.3 CD4-1- and 1.3 mCD3-hCD4c/ 
g-encoded transgenes identifies a number of possible candi- 
dates  for  the  sequences  that  mediate  human  CD4  sub- 
class-specific  expression  on peripheral  T  cells.  In  the  1.3 
mCD3-hCD4c/g construct, which is not expressed subclass 
specifically, the human CD4 promoter has been replaced by 
the mouse CD3-8 promoter. In addition,  the 1.3 mCD3- 
hCD4c/g transgene lacks several other human genomic se- 
quences that are present in 1.3 CD4-1; these include 5' and 
3' flanking sequences,  exon 1, introns 1-4, and an untrans- 
lated portion of exon 10. The experiments of Siu et al. (69) 
indicate that, in the mouse CD4 gene, the CD4 promoter 
itself may be a key component of the mechanism specifying 
subclass-specific expression. They found that a 172-bp frag- 
ment of the mouse CD4 promoter directed high levels of 
expression of a luciferase reporter in mature CD4 +  CD8-  T 
cell lines but not in mature CD4-CD8 + T cell lines. In ad- 
dition, they reported that the mouse CD4 promoter did not 
function in cloned immature CD4+CD8 § thymomas, un- 
less linked to the TCR ~  chain enhancer. This pattern of 
mouse CD4 promoter activity in cloned T cell lines recapit- 
ulates the pattern of CD4-1 transgene expression we observe 
in thymocytes and splenic T  cells. Such a finding suggests 
that the human CD4 promoter may mediate the CD4 subclass- 
specific expression of the CD4-1 transgene. However, although 
the human CD4 promoter present in the CD4-1 transgene 
responds to the CD4 enhancer in mature CD4 + ceils, the 
activity of the mouse CD4 promoter was not increased by 
a T cell-specific enhancer in mature CD4+CD8 -  lines. This 
difference between our results and the transient transcription 
studies of Siu et al. (69) may reflect an interaction between 
the CD4 enhancer and promoter that cannot be duplicated 
with the TCR B chain enhancer. 
In contrast to the findings of Siu et al. (69),  Sawada and 
Littman (62) reported that a CAT construct, driven by both 
the mouse CD4 promoter and enhancer, was active in CD4- 
CD8 +, as well as CD4 + cell lines.  Thus,  other sequences 
besides the CD4 promoter may be required in vivo to achieve 
CD4  subclass-specific  expression.  Interestingly, Sands  and 
Nikoli6-Zugi~ (70)  have identified T  cell-specific DNase I 
hypersensitive sites near the first exon and intron of the mouse 
Human CD4 Transgene CD4 gene that vary significantly in intensity in different CD4 
and CD8 subsets. They have proposed that proteins bound 
to DNA sequences at these sites may be involved in repressing 
CD4 transcription  during thymocyte development (70). In 
preliminary mapping experiments, we too have located DNase 
I hypersensitive sites within the first intron of the human 
CD4 gene (51; G. Wong and E. Lacy, unpublished results). 
Consistent with the premise that sequences in addition to 
the promoter are involved in specifying CD4 subclass-specific 
expression, the DNA sequences encoding these hypersensi- 
tive sites are present in CD4-1 but not in 1.3 mCD3-hCD4c/g. 
Using specifically  modified versions of the human CD4 trans- 
genes described in this paper, it will now be possible to define 
the identity and locations of the c/s-acting elements that di- 
rect CD4 gene expression to the mature CD4 §  CDS- T cell 
subset. 
The patterns of CD4-1 and 1.3 CD4-1 transgene expres- 
sion in spleen indicate that the 1.3-kb SphI-ClaI fragment 
produces T cell-specific expression of the CD4-1 construct 
not only by acting as an enhancer but also by inhibiting ex- 
pression in B cells (Figs. 2-4). Since the 1.3 mCD3-hCD4c/g 
construct was expressed in B cells (Fig. 7), the human en- 
hancer is not sufficient to preclude expression in B cells. Pre- 
sumably it must interact with sequences within CD4-1 to 
block B cell expression. It could accomplish this by permit- 
ting binding of a repressor and/or by preventing recognition 
and binding of B cell transcription  factors. Interestingly, al- 
though CD4 expression is not found on B cells in humans, 
it has been detected on a number of human B cell lines in 
culture (71-73). This indicates that the human gene does have 
an inherent ability to interact  functionally with transcrip- 
tion factors present in B cells. It also suggests that such cul- 
tured B cell lines lack the transcriptional controls responsible 
for maintaining the normal pattern of B cell-vs. T cell-specific 
gene expression. Possibly, in the human CD4 gene, these con- 
trois act through the 1.3-kb upstream enhancer identified in 
this  study. 
The nucleotide sequence of the 1.3-kb SphI-ClaI fragment 
argues that the HS4 DNase I hypersensitive site identifies the 
location of the human homologue of the mouse CD4 en- 
hancer defined by Sawada and Littman (62). Of the three 
DNase I footprints defined in the minimal mouse CD4 en- 
hancer, only the sequence of the CD4-3 site is conserved in 
the human CD4 enhancer (Fig. 8 B). This finding is consis- 
tent with the mutational analysis of the mouse CD4 enhancer, 
which showed that mutations in the CD4-3 site reduced en- 
hancer activity >90%, while mutations in the CD4-1 and/or 
CD4-2 sites generated  only a two- to fourfold loss of en- 
hancer activity (62). 11 regions of the 1.3-kb SphI-ClaI frag- 
ment were found to share homology  with a 772-bp sequence 
containing the mouse CD4 enhancer (Fig. 8 B). Two of these 
regions (902-926 with 69% homology and 1059-1085 with 
75% homology) lie outside the minimal mouse CD4 enhancer; 
a third region, and the one with the greatest sequence ho- 
mology (86%), does not contain any of the nuclear protein 
binding sites thus far defined within the minimal mouse CD4 
enhancer. Thus, in vivo, the CD4 enhancer may function 
through the binding of nuclear factors that were either ab- 
sent or undetectable in the nuclear extracts so far examined 
(62). With the identification of a construct that is expressed 
appropriately during thymic maturation in transgenic mice, 
it should now be possible to screen T cell lines for those that 
recapitulate the developmental regulation of the CD4 gene. 
Such lines may permit the identification  and isolation of  regula- 
tory proteins  that bind to the other regions  of homology 
shared by the mouse and human CD4 enhancers. 
Our analyses  of the CD4-1 and 1.3 CD4-1 transgenes dem- 
onstrate that c/s-acting sequences closely linked to the human 
CD4 gene direct CD4 expression to the CD4+CD8 -  ma- 
ture  T  cell  subset  and  preclude  CD4  expression  in  the 
CD4-CD8 + subset. However, these data do not establish 
whether the CD4 regulatory sequences respond  to signals 
generated  by  coengagement  of  an  MHC  molecule  by 
CD4/CD8 and a TCR, as predicted by the instruction model, 
or to signals produced by some other developmental event 
that commits a thymocyte to the CD4 lineage, as predicted 
by the stochastic/selection  model. 
Our observation  that the CD4-1 transgene  is expressed 
in splenic CD4 +  CD8-  T cells but not in thymocytes sug- 
gests that different mechanisms may operate to regulate the 
transcription  of the CD4 gene in immature and mature T 
cells. For example, one set of transcription  factors may be 
required to activate CD4  expression in CD4+CD8 + and 
CD4 +  CD8- thymocytes, and a second, distinct set of factors 
may drive expression in mature CD4 single-positive ceils. Our 
data, showing that the expression of the CD4-1 transgene 
in thymus is dependent on the 1.3-kb SphI-ClaI fragment, 
suggests that the activity of the first set of transcription factors 
would be mediated through the human enhancer. Possibly, 
the second set of factors would be brought into play only 
after positive selection of a class II-restricted TCR and/or 
export of a T cell to the periphery. Further studies in trans- 
genic mice should allow us to distinguish between reactiva- 
tion and repression as mechanisms for maintaining CD4 gene 
expression in the CD4+CD8 -  T cell subset and silencing 
it in the CD4-CD8 + T  cell subset. Deletion of sequence 
elements required for subclass-specific  expression should re- 
sult in CD4 expression in both the CD4 and CD8 subsets, 
if the loss of CD4  on CD4-CD8 + cells is  mediated by 
repression. On the other hand, deletion of these regulatory 
sequences would result in the absence of transgene expres- 
sion on both mature T cell subsets, if the subclass-specific 
expression of CD4 is generated by reactivation in class II-re- 
stricted  cells. 
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